Integrative Transcriptomic Meta-Analysis Reveals Risk Signatures and Immune Infiltration Patterns in High-Grade Serous Ovarian Cancer
Authors:
- Paula D. Morales-SuárezPaula D. Morales-Suárez
- Yina T. Zambrano-OYina T. Zambrano-O
- Alejandro Mejía-GarciaAlejandro Mejía-Garcia
- Hsuan Megan TsaoHsuan Megan Tsao
- Liliana Lopez-KleineLiliana Lopez-Kleine
- Diego A. BonillaDiego A. Bonilla
- Alba L. CombitaAlba L. Combita
- Rafel Parra-MedinaRafel Parra-Medina
- Patricia Lopez-CorreaPatricia Lopez-Correa
- Silvia J. Serrano-GSilvia J. Serrano-G
- Juliana L. RodriguezJuliana L. Rodriguez
- Carlos A. OrozcoCarlos A. Orozco
Open Access
Abstract
Background: High-grade serous ovarian cancer (HGSOC) is a highly aggressive malignancy with poor prognosis due to late-stage diagnosis and limited treatments. Identifying differentially expressed genes (DEGs), and immune cell infiltration patterns may improve prognostic assessment and therapeutic strategies. Methods: We conducted a meta-analysis of gene expression data from the GEO (Gene Expression Omnibus, NCBI). DEGs were identified, functionally enriched, and analyzed for protein-protein interactions. Overlaps with oncogenes and tumor suppressor genes were examined. Cox survival analysis and a gene expression-based risk stratification model were developed. Immune infiltration differences were assessed using deconvolution methods. Results: A total of 11 studies (291 HGSOC, 96 controls) identified 892 DEGs, mainly involved in mitochondrial function, vesicle trafficking, and immune regulation. Key oncogenes (EZH2, PDK1, ERBB2) and tumor suppressor genes (BRCA1, DUSP22) were identified. Survival analysis associated the expression of SEC24B, TGOLN2, TRAK1, and CAST with poor prognosis. Low-risk patients had higher activated dendritic cells and CD4+ memory T cells while high-risk patients were enriched in common lymphoid progenitors and megakaryocyte-erythroid progenitors. Conclusions: This study identifies key DEGs in HGSOC progression and presents a risk stratification model predicting patient outcomes.Keywords
Funding Information
- Instituto Nacional de Cancerología (INC) (Colombia) (ID: 19010300455)
This publication has 66 references indexed in Scilit:
- Current update on malignant epithelial ovarian tumorsAbdominal Radiology, 2021
- Gene Set Knowledge Discovery with EnrichrCurrent Protocols, 2021
- Prognostic gene expression signature for high-grade serous ovarian cancerAnnals of Oncology, 2020
- Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancerMedical Molecular Morphology, 2017
- TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high‐grade serous carcinoma—evidence supporting the clonal relationship of the two lesionsThe Journal of Pathology, 2011
- A Gene Signature Predictive for Outcome in Advanced Ovarian Cancer Identifies a Survival Factor: Microfibril-Associated Glycoprotein 2Cancer Cell, 2009
- A prognostic gene expression index in ovarian cancer—validation across different independent data setsThe Journal of Pathology, 2009
- Identification of TRAK1 (Trafficking protein, kinesin-binding 1) as MGb2-Ag: A novel cancer biomarkerCancer Letters, 2009
- Mouse Model of Human Ovarian Endometrioid Adenocarcinoma Based on Somatic Defects in the Wnt/β-Catenin and PI3K/Pten Signaling PathwaysCancer Cell, 2007
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986